Welcome to the 4th TCR-based Therapies for Solid Tumors Summit
The Only Forum Solely Dedicated to Advancing TCR Therapies Returns
The first TCR-based therapy approval in the US and Europe at the start of last year sparked a rush of excitement, investment and collaborations. As further developers move into the clinic and some near commercialization, it’s time for this community to unite to address the critical bottlenecks faced in development, from discovery to approval, to guarantee smooth sailing through the clinic.
The 4th TCR-based Therapies for Solid Tumors Summit is returning to Boston as the must-attend forum for TCR experts to come together to share industry updates and next generation engineered approaches to boost therapy safety and efficacy.
Join leaders and newcomers including Immunocore, Medigene, Immatics, Captain T Cell and Anocca as they collaborate to guarantee tumor-specificity, prevent cross-reactivity, boost TCR and target discovery, enhance solid tumor durability and explore TCR modalities.
Huge milestones were achieved for the TCR field in 2022, however, there’s no time to sit back and relax. Collaborate with like-minded TCR trailblazers to secure clinical validation and streamline the road from discovery to commercialization.
View the 2023 Agenda Now:
View the speaker faculty, full agenda details, partners and partnership opportunities, and how to access the best possible rates - all in one handy guide.
Expert Speakers Include:
Chief Commercial Officer
Chief Development Officer
Chief Scientific Officer
Vice President - Research
Chief Executive & Scientific Officer
Captain T Cell
“Wonderful opportunity to connect with experts and catch up on new developments in the TCR space”
Vice President, Precision & Translation Medicine, Affini-T Therapeutics
Companies Attending in 2023 Include:
Team Discounts Available:
3 Passes - 10% Discount
4 Passes - 15% Discount
5+ Passes - 20% Discount
Proud to Partner With:
“A great meeting to catch up with the latest advancements from the leaders in TCRs”
Vice President, Business Development, Immunocore